Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LuX: Xaluritamig in mCRPC
NCT07737925Phase 2Not yet recruiting
- Sponsor
- Thomas Jefferson University
- Start
- Oct 2026
- Primary completion
- Oct 2030
01
Overview
Phase 2, open-label, single-arm trial of xaluritamig in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Thomas Jefferson University. Primary endpoint: Proportion of Participants who achieve Partial or Complete Response or PSA90 at 24 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
xaluritamig
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07737925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07737925.